Диссертация (1174357), страница 27
Текст из файла (страница 27)
Serum lipids, postheparin plasma lipase activities and glucosetolerance in patients with prolactinoma / R. Pelkonen, E.A. Nikkil, B. Grahne // ClinEndocrinol (Oxf). – 1982. – Vol. 16 (4). – P. 383–390.167287. Peluso, J. Evidence for a genomic mechanism of action for progesteronereceptor membrane component-1 / J. Peluso, J. DeCerbo, V. Lodde // Steroids. – 2012.– Vol. 77 (10).
– P. 1007-1012.288. Peluso, J.J. Multiplicity of progesterone's actions and receptors in themammalian ovary / J.J. Peluso // Biol. Reprod. – 2006. – Vol. 75 (1). – P. 2-8.289. PIK3CA and PTEN mutations in uterine endometrioid carcinoma andcomplex atypical hyperplasia / M.P. Hayes [et al.] // Clin. Cancer Res. – 2006ю – Vol.12 (20 Pt 1). – P. 5932-5935.290. Predictive ability of estrogen receptor (ER), progesterone receptor (PR),COX-2, Mlh1, and Bcl-2 expressions for regression and relapse of endometrialhyperplasia treated with LNG-IUS: a prospective cohort study / I.D.
Gallos [et al.] //Gynecol. Oncol. – 2013. – Vol. 130 (1). – P. 58-63.291. Preliminarystudyofmembraneestrogenreceptorexpressionin endometrial carcinoma cells / Z.Q. Wang [et al.] // Zhonghua Fu Chan Ke Za Zhi. –2006. – Vol. 41 (7). – P. 471-475.292. Preoperative and postoperative agreement of histopathological findings incases of endometrial hyperplasia / P. Kleebkaow [et al.] Asian Pac.
J. Cancer Prev. –2008. – Vol. 9 (1). – P. 89-91.293. Preoperative and postoperative correlation of histopathological findings incases of endometrial hyperplasia / G. Gundem [et al.] // Eur. J. Gynaecol. Oncol. –2003. – Vol. 24 (3-4). – P. 330-333.294. Prevalence of endometrial polyps and abnormal uterine bleeding in a Danishpopulation aged 20—74 years / E. Dreisler [et al.] // Ultrasound Obstet. Gynecol.
–2009. – Vol. 33 (1). – P. 102-108.295. Progesterone receptor isoforms as a prognostic marker in human endometrialcarcinoma / S. Saito [et al.] // Cancer Sci. – 2006. – Vol. 97 (12). – P. 1308-1314.296. Progesterone receptors: various forms and functions in reproductive tissues /S. Gadkar-Sable [et al.] // Front. Biosci.
– 2005. – Vol. 10. – P. 2118-2130.168297. Progesterone signaling in human myometrium through two novel membraneg protein-coupled receptors: potential role in functional progesterone withdrawal at term/ E. Karteris [et al.] // Molecular Endocrinology. – 2006. – Vol. 20 (7). – P. 1519-1534.298. Progesterone regulation of human granulosa/luteal cell viability by anRU486-independent mechanism / L. Engmann [et al.] // J. Clin. Endocrinol.
– 2006. –91 (12). – P. 4962-4968.299. Progestin signaling through mPRα in Atlantic croaker granulosa/theca cellcocultures and its involvement in progestin inhibition of apoptosis / G.E. Dressing [etal.] // Endocrinology. – 2010. – Vol. 151 (12). – P. 5916–5926.300. Progestin upregulates G-protein-coupled receptor 30 in breast cancer cells /T.M. Ahola [et al.] // Eur. J. Biochem. – 2002. – Vol. 269 (10).
– P. 2485-2490.301. Prognostic importance of selected molecular immunohistochemical markersand DNA ploidy in endometrial cancer / M. Kudela [et al.] // Eur. J. Gynaecol. Oncol. –2012. – Vol. 33 (2). – P. 159-163.302. Prognostic significance of oestrogen receptor alpha (ERalpha)andbeta(ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas / N.Shabani [et al.] // Eur. J.
Cancer. – 2007. – Vol. 43 (16). – P. 2434-2444.303. Prolactin is an autocrine or paracrine growth factor for human myometrialand leiomyoma cells / R.A. Nowak [еt al.] // Gynecol. Obstet. Invest. – 1999. – Vol. 48(2). – P. 127-132.304. Prolactin--not only lactotrophin. A "new" view of the "old" hormone / M.Ignacak [et al.] // J. Physiol.
Pharmacol. – 2012. – Vol. 63 (5). – Р. 435-443.305. Prolonged use of gonadotropin-releasing hormone agonist and tibolone asadd-back therapy for the treatment of endometrial hyperplasia / T. Agorastos [ et al. ] //Maturitas. – 2004. – Vol. 48 (2). – P. 125-132.306. Prossnitz, E.R. The G-protein-coupled estrogen receptor GPER in health anddisease / E.R.
Prossnitz, M. Barton // Nat. Rev. Endocrinol. – 2011. – Vol. 7 (12). – P.715-726.307. Pru, J.K. PGRMC1 and PGRMC2 in uterine physiology and disease / J.K.Pru, N.C. Clark // Front. Neurosci. – 2013. – Vol. 7. – P. 168.169308. PTENmutationsandmicrosatelliteinstabilityincomplexatypicalhyperplasia, a precursor lesion to uterine endometrioid carcinoma / R.L. Levine [et al.]// Cancer Res.
1998. – Vol. 58 (15). – P. 3254-3258.309. Radowicki, S. Treatment of hyperplasia endometrium with GNRH agonists /S. Radowicki , K. Skórzewska // Ginekol. Pol. – 2003. – Bd. 74 (9). – S. 836-839.310. Recent advances in p53 research: an interdisciplinary perspective / M.Olivier [et al.] // Cancer Gene Ther. – 2009. – Vol. 16 (1). – P. 1-12.311. Regional adipose tissue metabolism in postmenopausal women aftertreatment with exogenous sex steroids / U.B. Lindberg [et al.] // Horm.
Metab. Res. –1990. – Vol. 22. – P. 345-351.312. Regressionofendometrialhyperplasiaaftertreatmentwiththegonadotrophin-releasing hormone analogue triptorelin: a prospective study / G.Grimbizis [et al.] // Hum. Reprod. – 1999. – Vol. 14 (2). – P. 479-484.313. Relative expression of progesterone receptors A and B in endometrioidcancers of the endometrium / R.L. Arnett-Mansfield [et al.] // Cancer Res.
– 2001. –Vol. 61 (11). – P. 4576-4582.314. Reproducibility of the diagnosis of atypical endometrial hyperplasia: aGynecologic Oncology Group study / R.J. Zaino [et al.] // Cancer. – 2006. – Vol. 106(4). – P. 804-811.315. Reversal by medical treatment of endometrial hyperplasia caused byestrogen replacement therapy / P.R. Figueroa-Casas, [et al.] // Menopause. – 2001. –Vol. 8 (6). – P. 420-423.316.
Risk of complex and atypical endometrial hyperplasia in relation toanthropometric measures and reproductive history / M. Epplein [et al.] // Am. J.Epidemiol. – 2008. – Vol. 168 (6). – P. 563-570.317. Risk of malignancy in endometrial polyps in premenopausal andpostmenopausal women according to clinicopathologic characteristics / L. Costa-Paiva[et al.] // Menopause. – 2011. – Vol. 18(12).
– Р. 1278-1282.170318. Risk of progression in complex and atypicalendometrial hyperplasia:clinicopathologic analysis in cases with and without progestogen treatment / L.C. Horn[et al.] // Int. J. Gynecol. Cancer. – 2004. – Vol. 14 (2). – P. 348-353.319. Risk of subsequent endometrial carcinoma associated with endometrialintraepithelial neoplasia classification of endometrial biopsies / J.V. Jr. Lacey [et al.] //Cancer. – 2008.
– Vol. 113 (8). – P. 2073-2081.320. Role of nuclear progesterone receptor isoforms in uterine pathophysiology /B. Patel // Human Reproduction Update. – 2014. – Vol. 21 (2). – P. 155-173.321. Sabry, M. Innovative oral treatments of uterine leiomyoma / M. Sabry, A.Al-Hendy // Obstet.
Gynecol. Int. –2012. – Vol. 2012. – P. 1–10.322. Saegusa, M. Changes in expression of estrogen receptors alpha and beta inrelation to progesterone receptor and pS2 status in normal and malignant endometrium /M. Saegusa, I. Okayasu // Jpn. J. Cancer Res. – 2000. – Vol.
91 (5). – P. 510-518.323. Saegusa, M. Progesterone therapy for endometrial carcinoma reduces cellproliferation but does not alter apoptosis / M. Saegusa, I. Okayasu // Cancer. – 1998. –Vol. 83. – P. 111-121.324. Samarnthai, N. Molecular Profiling of Endometrial Malignancies / N.Samarnthai, K. Hall, I.T. Yeh // Obstet. Gynecol. Int. – 2010. – Vol. 2010. – P. 162363.325. Schindler, A.E. Conservative therapeutic possibilities in glandular oradenomatous endometrial hyperplasia / A.E. Schindler // Zentralbl.
Gynecol. – 1996. –Vol. 118 (6). – P. 359-364.326. Selective down-regulation of progesterone receptor isoform B in poorlydifferentiated human endometrial cancer cells: implications for unopposed estrogenaction / N.S. Kumar [et al.] // Cancer Res. – 1998. – Vol. 58 (9). – P. 1860-1865.327. Serous endometrial cancers that mimic endometrioid adenocarcinomas: aclinicopathologic and immunohistochemical study of a group of problematic cases / F.Darvishian [et al.] // Am.
J. Surg. Pathol. – 2004. – Vol. 28 (12). – P. 1568–1578.328. Serum lipid profiles and cancer risk in the context of obesity: four metaanalyses / J.C. Melvin [et al.] // J. Cancer Epidemiol. – 2013. – ID 823849. – P. 12.171329. Shang, Y. Hormones and cancer / Y. Shang // Cell Res. – 2007. – Vol. 17(4). – P. 277-9.330. Shapiro, S. Risk of venous thromboembolism among users of oralcontraceptives: review of two recently published studies / S. Shapiro, J. Dinger // J.Fam. Plann. Reprod. Health Care. – 2010. – V. 36 (1).
– P. 33-38.331. Silverberg, S.G. Problems in the differential diagnosis of endometrialhyperplasia and carcinoma / S.G. Silverberg // Mod. Pathol. – 2000. – Vol. 13 (3). – P.309-327.332. Simple and rapid determination of norethindrone in human plasma bysupported liquid extraction and ultra performance liquid chromatography with tandemmass spectrometry / Z.
Gong [et al.] // Talanta. – 2012. – Vol. 91. – P. 77-82.333. Sivridis, E. The endometrial hyperplasias revisited / E. Sivridis, A.Giatromanolaki // Virhows Arch. – 2008. – Vol. 453 (3). – P. 223-231.334. Smuc, T. Aberrant pre-receptor regulation of estrogen and progesteroneaction in endometrial cancer / T. Smuc, T.L. Rizner // Mol. Cell. Endocrinol. – 2009. –Vol. 301 (1-2). – P. 74-82.335. Soltysik, K. Membrane estrogen receptors - is it an alternative way ofestrogen action? / K. Soltysik, P. Czekaj // J. Physiol. Pharmacol. – 2013. – Vol.
64 (2).– P. 129-142.336. Srinivas, S. Management of proliferative endometrium on biopsy in postmenopausal women / S. Srinivas, S. Maiti, P. Jothilakshmi // Journal of Gynecology andObstetrics. – 2016. – Vol. 4 (6). – P. 38-43.337. Steroid and G protein binding characteristics of the seatrout and humanprogestin membrane receptor alpha subtypes and their evolutionary origins / P. Thomas[et al.] // Endocrinol. – 2007. – Vol. 148 (2). – P. 705-718.338. Steroid receptors ERalpha, ERbeta, PR-A and PR-B are differentiallyexpressed in normal and atrophic human endometrium / I. Mylonas [et al.] // Histol.Histopathol. – 2007.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
